12
Oct
2020
Looking at Cancer From a Different Angle: Pearl Huang on The Long Run
Today’s guest on The Long Run is Pearl Huang. Pearl is the CEO of Cambridge, Mass.-based Cygnal Therapeutics. Cygnal is a startup dedicated to developing cancer drugs based on some fairly new understanding of the Peripheral Nervous System. For years, scientists assumed that the PNS was merely a conduit of the central nervous system. But what if the PNS is... Read More